Dipòsit Digital de Documents de la UAB 15 registres trobats  1 - 10següent  anar al registre: La cerca s'ha fet en 0.01 segons. 
1.
12 p, 700.5 KB Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain : OSIREX-Spanish Lung Cancer Group / Provencio, Mariano (Universidad Autónoma de Madrid) ; Terrasa, Josefa (Hospital Universitari Son Espases. Medical Oncology Department) ; Garrido, Pilar (IRYCIS Hospital Universitario Ramón y Cajal. Medical Oncology Department) ; Campelo, Rosario García (Instituto de Investigación Biomédica A Coruña INIBIC) ; Aparisi, Francisco (Hospital General Universitario de Valencia. Medical Oncology Department Valencia) ; Diz, Pilar (Complejo Asistencial Universitario de León. Medical Oncology Department León) ; Aguiar, David (Hospital Universitario de Gran Canaria Dr. Negrín. Medical Oncology Department) ; García-Giron, Carlos (Hospital Universitario De Burgos. Medical Oncology Department) ; Hidalgo, Julia (Hospital Lluís Alcanyis. Medical Oncology Department) ; Aguado, Carlos (Hospital Clínico San Carlos (Madrid)) ; González, Jorge García (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; Esteban, Emilio (Hospital Universitario Central de Asturias. Medical Oncology Department) ; Gómez-Aldavarí, Lorenzo (Complejo Hospitalario Universitario de Albacete) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Juan, Oscar (Hospital Universitari i Politècnic La Fe (València)) ; Chara, Luís Enrique (Hospital Universitario de Guadalajara. Medical Oncology Department) ; Marti, Juan L. (Hospital General Universitario de Alicante. Medical Oncology Department) ; Castro, Rafael López (Hospital Clínico Universitario (Valladolid)) ; Ortega, Ana Laura (Complejo Hospitalario de Jaén) ; Moreno, Elia Martínez (Hospital Virgen de la Salud. Medical Oncology Department) ; Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Sánchez Peña, Ana M. (Hospital Universitario de Getafe (Madrid)) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; Gastaldo, Amparo Sánchez (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Núñez, Natalia Fernández (Hospital Universitario Lucus Augusti. Medical Oncology Department) ; del Barco, Edel (Hospital Universitario de Salamanca. Medical Oncology Department) ; Cobo, Manuel (Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Unidad de Gestión Clínica Intercentros de Oncología Médica) ; Isla, Dolores (Hospital Universitario Lozano Blesa. Medical Oncology Department) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Navarro, Fátima (Hospital Universitario Príncipe de Asturias. Medical Oncology Department) ; Calvo, Virginia (Health Research Institute, Hospital Universitario Puerta de Hierro) ; Universitat Autònoma de Barcelona
AURA study reported 61% objective response rate and progression-free survival of 9. 6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain. [...]
2021 - 10.1186/s12885-021-07922-5
BMC Cancer, Vol. 21 (march 2021)  
2.
12 p, 1.2 MB Three-year outcome after transanal versus laparoscopic total mesorectal excision in locally advanced rectal cancer : a multicenter comparative analysis / de Lacy, F. B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Roodbeen, S. X. (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ; Ríos, J. (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; van Laarhoven, J. (Jeroen Bosch Ziekenhuis. Department of General Surgery) ; Otero-Piñeiro, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bravo, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Visser, T. (Gelderse Vallei Hospital. Department of Surgery) ; van Poppel, R. (Gelderse Vallei Hospital. Department of Surgery) ; Valverde, S. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Hompes, R. (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ; Sietses, C. (Gelderse Vallei Hospital. Department of Surgery) ; Castells, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bemelman, W. A. (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ; Tanis, P. J. (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ; Lacy, A. M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
For patients with mid and distal rectal cancer, robust evidence on long-term outcome and causal treatment effects of transanal total mesorectal excision (TaTME) is lacking. This multicentre retrospective cohort study aimed to assess whether TaTME reduces locoregional recurrence rate compared to laparoscopic total mesorectal excision (LapTME). [...]
2020 - 10.1186/s12885-020-07171-y
BMC Cancer, Vol. 20 (july 2020)  
3.
7 p, 406.2 KB Genetic polymorphisms of FAS and EVER genes in a Greek population and their susceptibility to cervical cancer : a case control study / Pavlidou, Evangelia. (Geneva University Hospitals. Department of Gynaecology and Obstetrics) ; Daponte, Alexandros (University of Thessaly. Department of Obstetrics and Gynaecology. Faculty of Medicine) ; Egea, Raquel (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Dardiotis, Efthimios (University of Thessaly. Department of Neurology) ; Hadjigeorgiou, Georgios M. (University of Thessaly. Department of Neurology) ; Barbadilla Prados, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Agorastos, Theodoros (Hippokrateion General Hospital of Thessaloniki)
Background: the aim of the study was to evaluate the association of two SNPs of EVER1/2 genes' region (rs2290907, rs16970849) and the FAS-670 polymorphism with the susceptibility to precancerous lesions and cervical cancer in a Greek population. [...]
2016 - 10.1186/s12885-016-2960-3
BMC Cancer, Vol. 16 (2016) , art. 923  
4.
12 p, 2.8 MB Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer / Bermudo, Raquel (Institut de Biologia Molecular de Barcelona) ; Abia, David (Centro de Biología Molecular Severo Ochoa) ; Ferrer, Berta (Hospital Clinic, CIBERehd. Department of Pathology) ; Nayach, Iracema (Hospital Clinic, CIBERehd. Department of Pathology) ; Benguria, Alberto (Centro Nacional de Biotecnología. Departamento de Inmunología y Oncología) ; Zaballos, Ángel (Centro Nacional de Biotecnología. Departamento de Inmunología y Oncología) ; Del Rey Azpiri, Javier (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Miró, Rosa (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Martínez-A, Carlos (Centro Nacional de Biotecnología. Departamento de Inmunología y Oncología) ; Ortiz, Ángel R. (Centro de Biología Molecular Severo Ochoa) ; Fernández, Pedro L. (Hospital Clinic, CIBERehd. Department of Pathology) ; Thomson, Timothy M. (Institut de Biologia Molecular de Barcelona)
Background: transcriptional profiling of prostate cancer (PC) has unveiled new markers of neoplasia and allowed insights into mechanisms underlying this disease. Genomewide analyses have also identified new chromosomal abnormalities associated with PC. [...]
2008 - 10.1186/1471-2407-8-315
BMC Cancer, Vol. 8 (2008) , art. 315  
5.
26 p, 11.1 MB The role of clonal communication and heterogeneity in breast cancer / Martín-Pardillos, A. (Centro de Investigación Biomédica en Red de Cáncer) ; Valls Chiva, Á. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Bande Vargas, G. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hurtado Blanco, P. (Cancer Modelling Lab. Roche-CHUS Joint Unit) ; Piñeiro Cid, R. (Cancer Modelling Lab. Roche-CHUS Joint Unit) ; Guijarro, P.J. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hümmer, S. (Centro de Investigación Biomédica en Red de Cáncer) ; Bejar Serrano, E. (Centro de Investigación Biomédica en Red de Cáncer) ; Rodriguez-Casanova, A. (Cancer Epigenomics. Translational Medical Oncology (Oncomet). Health Research Institute of Santiago (IDIS). University Clinical Hospital of Santiago (CHUS)) ; Díaz-Lagares, Angel (Cancer Epigenomics. Translational Medical Oncology (Oncomet). Health Research Institute of Santiago (IDIS). University Clinical Hospital of Santiago (CHUS)) ; Castellvi, J. (Hospital Universitari Vall d'Hebron) ; Miravet-Verde, S. (EMBL/CRG Systems Biology Research Unit. Centre for Genomic Regulation (CRG). Institute of Science and Technology) ; Serrano, L. (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Lluch-Senar, M. (EMBL/CRG Systems Biology Research Unit. Centre for Genomic Regulation (CRG). Institute of Science and Technology) ; Sebastian, V. (Networking Research Centre on Bioengineering. Biomaterials and Nanomedicine. CIBER-BBN) ; Bribian, A. (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; López-Mascaraque, L. (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; López-López, R. (Roche-CHUS Joint Unit. University Clinical Hospital of Santiago (CHUS)) ; Ramón Y Cajal, S. (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Background: Cancer is a rapidly evolving, multifactorial disease that accumulates numerous genetic and epigenetic alterations. This results in molecular and phenotypic heterogeneity within the tumor, the complexity of which is further amplified through specific interactions between cancer cells. [...]
2019 - 10.1186/s12885-019-5883-y
BMC Cancer, Vol. 19 Núm. 1 (may 2019) , p. 666  
6.
10 p, 834.6 KB Health services research in patients with breast cancer (CAMISS-prospective) : study protocol for an observational prospective study / García-Gutierrez, Susana (Hospital de Galdakao (Usansolo, Biscaia)) ; Orive, Miren (Hospital de Galdakao (Usansolo, Biscaia)) ; Sarasqueta, Cristina (Hospital Universitario Donostia - Red de Investigación en Servicios de Salud en Enfermedades Crónicas [REDISSEC]) ; Legarreta, Maria Jose (Universidad del País Vasco) ; Gonzalez, Nerea (Hospital de Galdakao (Usansolo, Biscaia)) ; Redondo, Maximino (Agencia Sanitaria Costa del Sol) ; Rivero, Amado (Fundación Canaria de Investigación y Salud) ; Serrano-Aguilar, Pedro (Servicio Canario de la Salud) ; Castells, Xavier (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; Quintana, Jose Maria (Hospital de Galdakao (Usansolo, Biscaia)) ; Sala, Maria (Institut Hospital del Mar d'Investigacions Mèdiques)
Though breast cancer remains a major health problem, there is a lack of information on health care provided to patients with this disease and associated costs. In addition, there is a need to update and validate risk stratification tools in Spain. [...]
2018 - 10.1186/s12885-017-3926-9
BMC Cancer, Vol. 18 (january 2018)  
7.
11 p, 542.8 KB A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer / Reynolds, Kerry Lynn ; Bedard, Philippe L. (Toronto, ON Canada) ; Lee, Se-Hoon (Seoul, Republic of Korea) ; Lin, Chia-Chi (Taipei, Taiwan) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Alsina, Maria (Hospital Universitari Vall d'Hebron) ; Cohen, Ezra (La Jolla, CA USA) ; Baselga Torres, Josep, 1959-2021, (New York, NY USA) ; Blumenschein, George (Houston, TX USA) ; Graham, Donna M. (Toronto, ON Canada) ; Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ; Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ; Sharma, Sunil (Salt Lake City, UT USA) ; Salgia, Ravi (Duarte, CA USA) ; Seroutou, Abdelkader (Basel, Switzerland) ; Tian, Xianbin (East Hanover, NJ USA) ; Fernandez, Rose (East Hanover, NJ USA) ; Morozov, Alex (New York, NY USA) ; Sheng, Qing (Cambridge, MA USA) ; Ramkumar, Thiruvamoor (East Hanover, NJ USA) ; Zubel, Angela (Basel, Switzerland) ; Bang, Yung-Jue (Seoul, Republic of Korea) ; Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)  
8.
6 p, 538.4 KB Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer / Bonanno, Laura (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ; Costa Ribalta, Carlota (Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Sanchez, Jose-Javier (Universidad Autónoma de Madrid) ; Rodriguez, Ignacio (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ; Gimenez-Capitan, Ana (Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain) ; Molina-Vila, Miquel Angel (Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain) ; Vergnenegre, Alain (Hospital du Cluzeau, 23, rue Larey, Limoges, France) ; Massuti, Bartomeu (Hospital General Universitari d'Alacant) ; Favaretto, Adolfo (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ; Rugge, Massimo (Cytology and Pathology, Università degli Studi di Padova, Via Gabelli 61, Padova, Italy) ; Pallares, Cinta (Institut d'Investigació Biomèdica Sant Pau) ; Taron, Miquel (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ; Rosell, Rafael (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ; Universitat Autònoma de Barcelona
BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. [...]
2016 - 10.1186/s12885-016-2339-5
BMC Cancer, Vol. 16 (may 2016)  
9.
11 p, 912.9 KB Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis / Capdevila, Jaume (Hospital Universitari Vall d'Hebron) ; Sevilla, Isabel (Hospital Universitario Virgen de la Victoria) ; Alonso, Vicente (Medical Oncology Department, Hospital Universitario Miguel Servet) ; Antón Aparicio, Luís (Complejo Hospitalario Universitario A Coruña) ; Jiménez Fonseca, Paula (Hospital Universitario Central de Asturias) ; Grande, Enrique (Hospital Universitario Ramón y Cajal) ; Reina, Juan José (Hospital Universitario Virgen de la Macarena) ; Manzano, José Luís (Hospital Universitari Vall d'Hebron) ; Alonso Lájara, Juan Domingo (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ; Barriuso, Jorge (Hospital Universitario La Paz (Madrid)) ; Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ; Medina, Javier (Complejo Hospitalario de Toledo) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Segura, Ángel (Hospital Universitario La Fe University Hospital) ; Carrera, Sergio (Hospital Universitario de Cruces) ; Crespo, Guillermo (Hospital Universitario de Burgos) ; Fuster, José (Hospital Universitario Son Dureta) ; Munarriz, Javier (Hospital Provincial de Castelló) ; García Alfonso, Pilar (Hospital Gregorio Marañón (Madrid)) ; Universitat Autònoma de Barcelona
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). [...]
2015 - 10.1186/s12885-015-1512-6
BMC Cancer, Vol. 15 (july 2015)  
10.
14 p, 2.0 MB Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential : a molecular and clinicopathological study / Gonzalo Calvo, David de (Institut d'Investigació Biomèdica Sant Pau) ; López Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Nasarre, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Perez Olabarria, Maitane (Institut d'Investigació Biomèdica Sant Pau) ; Vázquez, Tania (Institut d'Investigació Biomèdica Sant Pau) ; Escuin i Borràs, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Badimon, Lina (Institut de Ciències Cardiovasculars de Catalunya) ; Barnadas Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Lerma Puertas, Enrique (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Llorente Cortés, Vicenta (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Background: The metabolic effect of intratumor cholesteryl ester (CE) in breast cancer remains poorly understood. The objective was to analyze the relationship between intratumor CE content and clinicopathological variables in human breast carcinomas. [...]
2015 - 10.1186/s12885-015-1469-5
BMC Cancer, Vol. 15 N. 460 (June 2015) , p. 1-13  

Dipòsit Digital de Documents de la UAB : 15 registres trobats   1 - 10següent  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.